VIVES is a multi-sector fund that invests in projects with a positive societal impact
3D-Side assists surgeons by integrating 3D technologies into the operating room. They combine the precision of engineering with medical expertise to individualize the surgical treatment of each...
Nuclidium is a clinical-stage biotechnology company specializing in the development of next-generation copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted...
Viridaxis is a specialist in development and supply of efficient and effective natural aphid control methods for the agricultural sector. Their R&D activities include applied field research to...
Denis Périquet, CEO Tessares:
"VIVES supports real innovation projects, while understanding that those projects need time to grow from the academic research phase to a commercial success. Team...
Eric de La Fortelle, Venture Partner at Seventure Partners:
"The tech transfer organization SOPARTEC and the associated fund VIVES played a key role in the initial structuring and the foundation of...
Pierre Blondeau, CEO Upstreem:
"We have been working since 2017 with VIVES II, which has joined us since the beginning of our adventure. VIVES II team has an in-depth understanding of all aspects of...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is
NVD003 is a bone grafting material developed to surgically treat patients with Congenital Pseudarthrosis of the Tibia, a rare and difficult-to-treat pediatric disease
Four young patients were treated